LARIAM

This brand name is authorized in Austria, Estonia, Finland, France, Malta, Netherlands, United Kingdom, South Africa

Active ingredients

The drug LARIAM contains one active pharmaceutical ingredient (API):

1 Mefloquine UNII 5Y9L3636O3 - MEFLOQUINE HYDROCHLORIDE

Mefloquine acts on and destroys the asexual intraerythocytic forms of the human malaria parasites: Plasmodium falciparum, P. vivax. P. malariae and P. ovale. It is effective in the treatment and prophylaxis of malaria. Read about Mefloquine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LARIAM Tablets	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
P01BC02	Mefloquine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BC Methanolquinolines
Discover more medicines within P01BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1010091
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 005884
Country: FR	Base de données publique des médicaments	Identifier(s): 65999556
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 147636, 21869
Country: MT	Medicines Authority	Identifier(s): AA565/24202
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 25410
Country: ZA	Health Products Regulatory Authority	Identifier(s): 28/20.2.6/0104